Joe Lennerz

Joe Lennerz

Harvard University

H-index: 63

North America-United States

About Joe Lennerz

Joe Lennerz, With an exceptional h-index of 63 and a recent h-index of 53 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Diagnostics, Implementation Sciences, Biomarker, Reimbursement.

His recent articles reflect a diverse array of research interests and contributions to the field:

POLYMER-BASED INTERFACE TARGETING INFLAMMATION IN ULCERATIVE COLITIS

Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence Models

Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real …

Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer

The Idylla™ IDH1-2 Mutation Assay Kit: A tool for mutation detection in IDH1 and IDH2 genes

Quantifying cell divisions along evolutionary lineages in cancer

Customized liquid biopsy assay for monitoring EWSR1 fusions in sarcomas

Training pathologists to assess stromal tumour‐infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research

Joe Lennerz Information

University

Position

Massachusetts General Hospital/Harvard Medical School

Citations(all)

18264

Citations(since 2020)

11940

Cited By

10352

hIndex(all)

63

hIndex(since 2020)

53

i10Index(all)

166

i10Index(since 2020)

149

Email

University Profile Page

Harvard University

Google Scholar

View Google Scholar Profile

Joe Lennerz Skills & Research Interests

Diagnostics

Implementation Sciences

Biomarker

Reimbursement

Top articles of Joe Lennerz

Title

Journal

Author(s)

Publication Date

POLYMER-BASED INTERFACE TARGETING INFLAMMATION IN ULCERATIVE COLITIS

Gastroenterology

Sufeng Zhang

Amy Jin

Jochen Lennerz

Joshua Korzenik

Carlo Traverso

2024/2/1

Reproducible Reporting of the Collection and Evaluation of Annotations for Artificial Intelligence Models

Modern Pathology

Katherine Elfer

Emma Gardecki

Victor Garcia

Amy Ly

Evangelos Hytopoulos

...

2024/4/1

Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real …

JCO oncology practice

Jeffrey A Scott

Jochen Lennerz

Melissa Lynne Johnson

Lucio N Gordan

Robert H Dumanois

...

2024/1

Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer

Chowdhury Arif Jahangir

David B Page

Glenn Broeckx

Claudia A Gonzalez

Caoimbhe Burke

...

2024/1/17

The Idylla™ IDH1-2 Mutation Assay Kit: A tool for mutation detection in IDH1 and IDH2 genes

Cancer Research

Bram De Craene

Katrien Trappeniers

Ana Marcelino

Lee Robertson

Phillippe Taniere

...

2024/3/22

Quantifying cell divisions along evolutionary lineages in cancer

Kamila Naxerova

Martin Blohmer

David Cheek

Wei-Ting Hung

Maria Kessler

...

2024/1/12

Customized liquid biopsy assay for monitoring EWSR1 fusions in sarcomas

Cancer Research

Annie Li

Julia C Thierauf

Bianca Gonda

Rashi Purohit

Stefan T Kaluziak

...

2024/3/22

Training pathologists to assess stromal tumour‐infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research

Amy Ly

Victor Garcia

Kim RM Blenman

Anna Ehinger

Katherine Elfer

...

2024

Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart

Circulation

Jana Grune

Geetika Bajpai

Pervin Tülin Ocak

Eva Kaufmann

Kyle Mentkowksi

...

2024/3/20

Radical surgical resection with molecular margins is associated with improved survival in IDH wildtype GBM

Neuro-oncology

Elie Massaad

William J Smith

Joseph Bradley

Eric Esposito

Mihir Gupta

...

2024/4/6

Diagnostic Test Utilization Management Strategies as an Opportunity for Equitable Access to Molecularly Informed Clinical Care

The Journal of Applied Laboratory Medicine

Helen X Hou

Annie Li

Julia C Thierauf

Jochen K Lennerz

2024/1

Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

Cancer Discovery

Andreas Varkaris

Ferran Fece de la Cruz

Elizabeth E Martin

Bryanna L Norden

Nicholas Chevalier

...

2024/2/8

Abstract LB449: Strategies to overcome resistance to PI3Kalpha-selective inhibitors mediated by acquired alterations in the PI3K/AKT pathway

Cancer Research

Ferran Fece de la Cruz

Andreas Varkaris

Elizabeth E Martin

Bryanna L Norden

Nicholas Chevalier

...

2024/4/5

Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration

JCO Oncology Practice

Laura M Spring

Lindsey Mortensen

Elizabeth Abraham

Jennifer Keenan

Arielle Medford

...

2024/1

Sensitivity to ALK-Directed Therapy in Osteosarcoma With an Acquired ALK Rearrangement

JCO Precision Oncology

Zehra Ordulu

Peter Giunta

Wei-Ting Hung

Yin P Hung

Judit Simon

...

2023

Abstract P5-02-13: TRK inhibitor in a patient with metastatic triple negative breast cancer and NTRK fusions identified via cell-free DNA analysis

Cancer Research

Jennifer C Keenan

Arielle J Medford

Lauren J Oshry

Baris Boyraz

Charles S Dai

...

2023/3/1

Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.

Jeffrey A Scott

Harvey I Katzen

Jochen K Lennerz

Melissa Lynne Johnson

Lucio N Gordan

...

2023/6/1

380 A Rapid CSF Assay Accelerates Diagnosis and Treatment Initiation for CNS Neoplasms

Neurosurgery

Mihir Gupta

Joseph Bradley

Elie Massaad

Evan Burns

Deborah Forst

...

2023/4/1

Link to this full text: http://hdl. handle. net

ONCOLOGY

Riccardo Autorino

Pierluigi Bove

Marco De Sio

Roberto Miano

Salvatore Micali

...

2023/1/9

Efficacy and tolerability of ALK/MET combinations in patients with ALK-rearranged lung cancer with acquired MET amplification: a retrospective analysis

JTO Clinical and Research Reports

Ibiayi Dagogo-Jack

Lesli A Kiedrowski

Rebecca S Heist

Jessica J Lin

Catherine B Meador

...

2023/8/1

See List of Professors in Joe Lennerz University(Harvard University)